Yangcheng Evening News interviewed executives from several biomedical-related companies in the province, all of whom unanimously expressed optimism about the future of Guangdong's biomedical industry and agreed that the initiatives in the action plan are very beneficial to the development of companies.

After years of development, the biomedical industry in Guangdong has established a certain foundation and advantage. In 2023, the biomedical and health industry cluster in Guangdong achieved a revenue of 663.8 billion yuan, ranking among the top in the country. Chen Xianshuai, Chairman of Guangdong Zhongke Anchi Biotechnology Co., Ltd.(CASANGELS) , believes that Guangdong has a clear advantage in further developing the biomedical industry.

He said: "Guangdong's solid foundation in high-end manufacturing provides strong support for the development of the biomedical industry. Guangdong also has many high-level hospitals, which provide favorable conditions for the research and development, clinical application, and market transformation of biomedical products. At the same time, Guangdong is adjacent to Hong Kong and Macao, and biomedical companies can better utilize the advantages of Hong Kong and Macao for more convenient and rapid clinical trials of biomedical products."

Lin Jian, Deputy General Manager of Bio-Thera Solutions Co., Ltd., also shares the same view. He stated that in the subfield of biopharmaceuticals, Guangdong already has dozens of related companies with an output value close to 100 billion yuan, gathering about 30,000 professional talents, forming an industrial cluster effect, and showing a clear upward trend.

When discussing which initiatives in the "Action Plan" will specifically benefit the future development of companies, Chen Xianshuaisaid that the plan proposes many substantial support measures, including subsidies and financial assistance in product registration, application, and scientific research and development, which are a great help for companies' research and market promotion. The plan also mentions several times the acceleration of various approval processes, which means that companiescan bring products to the market more quickly.

Lin Jian said that the action plan mentions the release of a catalog of biomedical innovative drugs and medical devices approved in Guangdong, and according to the principle of "allocating as much as possible," it promotes the acceleration of hospital applications, which will help solve some problems encountered by companies in the market.

10月9日，广东对外印发《关于进一步推动广东生物医药产业高质量发展的行动方案》，提出38项重点任务和举措，力争到2027年，广东生物医药与健康产业集群规模超万亿元。

羊城晚报采访了多家省内生物医药相关企业的高管，他们一致看好广东生物医药产业的前景，且均认为该行动方案中的举措对企业的发展十分有益。

广东生物医药产业经过多年发展，已建立起一定的基础和优势，2023年，广东生物医药与健康产业集群实现营收6638亿元，位居全国前列。广东中科安齿生物科技有限公司董事长陈贤帅认为广东进一步发展生物医药产业优势明显。

他说：“广东良好的高端制造业基础为生物医药产业的发展提供了坚实的支撑。广东还拥有众多高水平的医院，为生物医药的研发、临床应用和市场转化提供了有利条件。同时，广东毗邻港澳，生物医药企业可以更好地利用香港和澳门进行生物医药临床试验更便捷、快速的优势。”

百奥泰生物制药股份有限公司副总经理林键也有同感，他表示，在生物制药这一细分领域，广东已有数十家相关企业，产值接近千亿元，聚集了约3万名专业人才，形成了产业集群效应，上升态势明显。

在谈到“行动方案”中哪些举措将具体利好企业未来发展时，陈贤帅表示，方案中提出了许多实质性的支持措施，包括产品注册、运用、科研研发等方面的补贴和资助，这对于企业的研发和市场推广都是极大的助力。方案中还多次提到各类审核流程的加快，这对于生产企业来说，意味着能够更快地将产品推向市场。

林键则表示，该行动方案提到将发布广东已获批生物医药创新药械产品目录，并按照“应配尽配”原则，推动加快入院应用，这将有助于解决企业在市场端遇到的一些问题。

澳门开彩开奖+结果2022历史100期

「活动」首次登录送67元红包

300.26MB

版本V9.43.89

下载APK 高速下载

下载澳门开彩开奖+结果2022历史100期安装你想要的应用更方便更快捷发现更多

82%好评(365人)

752

详细信息

软件大小: 517.62MB
最后更新: 2024-10-10 15:29:08
最新版本: V55.95
文件格式: apk
应用分类:ios-Android 澳门开彩开奖+结果2022历史100期
使用语言: 中文
: 需要联网
系统要求: 5.41以上

应用介绍

一，澳门开彩开奖+结果2022历史100期91九色经典无码在线
二，澳门开彩开奖+结果2022历史100期澳门彩三肖三码
三，澳门开彩开奖+结果2022历史100期，日韩人体激情35p
四，澳门开彩开奖+结果2022历史100期，Squirting潮喷在线观看
五，澳门开彩开奖+结果2022历史100期，粗喘进入娇吟
六，澳门开彩开奖+结果2022历史100期，欧美极品jIZZHD欧美黑人
七，D黑人社长人妻秘书
【联系我们】
客服热线：1333-0405-151

加载更多

版本更新

V6.15

加载更多